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As one of the leading causes of blindness, age-related macular degeneration (AMD) has remained at the epicenter of clinical research
in ophthalmology. During the past decade, focus of researchers has ranged from understanding the role of vascular endothelial
growth factor (VEGF) in the angiogenic cascades to developing new therapies for retinal vascular diseases. Anti-VEGF agents such
as ranibizumab and aflibercept are becoming increasingly well-established therapies and have replaced earlier approaches such as
laser photocoagulation or photodynamic therapy. Many other new therapeutic agents, which are in the early phase clinical trials,
have shown promising results. The purpose of this paper is to briefly review the available treatment modalities for neovascular
AMD and then focus on promising new therapies that are currently in various stages of development.

1. Introduction
Age-related macular degeneration (AMD) is the leading
cause of visual loss in developed countries in individuals
over the age of 50 years. Two types of AMD have been
reported: nonneovascular (dry AMD) and neovascular (wet
AMD). Neovascular AMD is less common, affecting only
10% of AMD patients [1]. However, it is more likely to lead
to significant visual loss. Neovascular AMD is characterized
by choroidal neovascularization (CNV) development (immature pathological vessels grow from the choroid towards the
retina). Leakage from these immature vessels leads to exudation and hemorrhage. Without treatment, the condition
causes irreversible damage to the retinal layers and yields
central visual loss.
The management of neovascular AMD has markedly
changed over the past decade. The approval of pegaptanib
sodium (Macugen) in December 2004 by the Food and
Drug Administration (FDA) marked the beginning of the

molecular era in the treatment of neovascular AMD. Subsequently, the introduction of ranibizumab, bevacizumab, and
aflibercept has dramatically changed the treatment paradigm
of AMD-related CNV [2].
Promising therapeutic molecules continue to emerge and
exert their influence through a variety of mechanisms. Some
molecules target vascular endothelial growth factor (VEGF),
a key player in the disease process, while other molecules have
different targets along the angiogenesis cascades.

2. Previously Established Therapies
2.1. Laser Photocoagulation. Laser photocoagulation works
on the principle of cauterizing the feeder vessels of the
subfoveal CNV, thus halting subretinal fluid accumulation
and preventing progression of the disease [3].
The Macular Photocoagulation Study (MPS) compared
the usefulness of laser photocoagulation to observation in
preventing severe visual loss in patients with neovascular
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AMD. The study results showed that 60% of nontreated eyes
had experienced severe visual loss contrasted to 25% of the
treated eyes. This magnitude of benefit observed with laser
treatment unjustified withholding of laser treatment from
eyes in the observation group and led to early termination
of recruitment [3, 4].
Combination therapy of laser with other modalities may
also lead to potential benefits. However, the incidence of
recurrent and persistent CNV after laser treatment decreases
the long term effectiveness of this method of therapy [5].
Overall, laser photocoagulation for neovascular AMD
may help to slow the progression of vision loss in the
long run. However, it may be associated with increased
risk of vision loss during the early stage after treatment
which lasts for longer durations with subfoveal CNV. Taking
this concern into consideration, laser photocoagulation is
not recommended with subfoveal CNV, especially with the
advent of the several other pharmacologic therapies [6].
2.2. Verteporfin (Visudyne, Novartis, Basil, Switzerland).
Photodynamic therapy (PDT), first approved in July 2000 for
subfoveal CNV, uses light-activated verteporfin to damage
fibrovascular tissue by inducing occlusion of new vessels
[7]. The Visudyne in Occult (VIO) study for occult CNV
compared the change in best corrected visual acuity (BCVA)
from baseline to 12 and 24 months between PDT and placebo.
Out of 364 patients with occult CNV, 244 patients were
assigned to PDT and 120 patients were assigned to the placebo
group. Thirty-seven percent and 47% of patients treated with
verteporfin lost 15 letters or more at 12 months and 24
months, respectively, versus 45% and 53% in the placebo
group. Verteporfin-treated patients who lost 30 letters or
more at these two endpoints were 16% and 24% respectively
versus 17% and 25% in the placebo group [8].
2.3. Antivascular Endothelial Growth Factor
2.3.1. Pegaptanib Sodium (Macugen, EyeTech, New York, NY,
USA). Pegaptanib is a 28-base RNA aptamer that binds
selectively and inhibits activation of VEGF-A165 , which is
the most prevalent isoform of VEGF in neovascular AMD
[9, 10]. VEGF inhibition Study in Ocular Neovascularization
(VISION) was a double-masked, randomized, controlled trial
that evaluated three different doses of intravitreal (IVT)
pegaptanib sodium for neovascular AMD. A total of 1208
patients were randomized to four groups (who received
0.3 mg, 1.0 mg, and 3.0 mg pegaptanib sodium), respectively,
in addition to a sham group. Patients were administered
IVT pegaptanib every 6 weeks over a period of 48 weeks.
A loss of fewer than 15 letters was observed in 65 to 70%
of patients who received pegaptanib (𝑃 ≤ 0.03) compared
to 55% of patients in the sham group at week 54. Severe
vision loss of ≥ 30 letters was observed in 8 to 14% of
patients who received pegaptanib injection inclusive of all
the treatment arms compared to 22% in the sham group.
Ocular adverse events (AEs) that occurred more commonly
in the study eyes of patients getting IVT pegaptanib included
eye pain (34%), vitreous floaters (33%), punctuate keratitis
(32%), and increased intraocular pressure (IOP) (20%). The
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intravitreal injection of pegaptanib was not associated with
the potential VEGF inhibition-related systemic AEs recognized with systemic administration of VEGF inhibitors such
as hemorrhagic events, thromboembolic events, and vascular
hypertensive disorders [9].
2.3.2. Ranibizumab (Lucentis; Genentech, Inc., South San
Francisco, CA, USA). Ranibizumab is a recombinant, humanized monoclonal antibody fragment that inhibits all
active isoforms of VEGF-A. In the anti-VEGF antibody for the
Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) study, which compared PDT
with ranibizumab, a mean reduction of 9.8 letters was found
in the PDT arm compared to a gain of 8.1 to 10.7 letters in the
ranibizumab arm, validating the effectiveness of ranibizumab
as a therapy for the improvement of vision in patients with
neovascular AMD [11].
In addition to the ANCHOR study, the Minimally Classic/Occult Trial of the anti-VEGF antibody ranibizumab
in the Treatment of Neovascular AMD (MARINA) study
showed that 94.5% of patients receiving 0.3 mg and 94.6% of
patients receiving 0.5 mg dose of ranibizumab lost ≤15 letters
at 12 months compared to 62.2% in the sham group. Twentyfive percent of patients receiving 0.3 mg and 33% patients
receiving 0.5 mg ranibizumab gained ≥15 letters at 12 months,
which remained stable at 24 months as compared to 5.0%
in the sham group. There was a mean increase of 6.5 and
7.2 letters in 0.3 mg and 0.5 mg groups, respectively, versus a
mean decrease of 10.2 letters in the sham group. The rate of
reported endophthalmitis was 1.0% (5 out of 447 patients).
Stroke occurred at a rate of 0.8% in sham group, 1.3% in the
0.3 mg group, and 2.5% in the 0.5 mg group [12].
The Safety of Intravitreal Lucentis for AMD (SAILOR)
study had two cohorts of patients. Cohort 1 was randomized
in a 1 : 1 to receive 3 consecutive monthly injections of 0.3 mg
or 0.5 mg ranibizumab then retreated based on visual acuity
(VA) and retinal thickness values. Each group was further
stratified into treatment naı̈ve and treated patients. Cohort 2
patients received 3 consecutive monthly injections of 0.5 mg
ranibizumab and were retreated afterwards at the discretion
of the investigator. Treatment-naı̈ve patients gained 5.8 letters
with 0.3 mg dose and 7.0 letters with 0.5 mg dose at 3 months.
The gain was 0.5 and 2.3 letters for the 0.3 mg and 0.5 mg
groups, respectively, at 12 months. For the previously treated
patients, 4.6 and 5.8 letter-gain were observed in the 0.3 and
0.5 mg groups respectively at 3 months, whereas 0.3 and 1.7
letter-gain were observed at 12 months. A large number of
Cohort 2 patients discontinued from the study, which was
noted during data analysis. Overall, the median Snellen VA
improved from 20/100 to 20/80 at months 6 and 12. Less
than 1% patients in Cohort 1 and 0.1% in Cohort 2 developed
endophthalmitis. Among nonocular SAEs, 0.7% and 1.2%
patients in 0.3 mg and 0.5 mg ranibizumab group suffered
from stroke, respectively, at 12 months [13].
2.3.3. Bevacizumab (Avastin, Genentech, Inc., South San Francisco, CA, USA). Bevacizumab is a full-length humanized
monoclonal antibody that targets all isoforms of VEGF-A.
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Currently, bevacizumab is the most widely used anti-VEGF
agent throughout the world for treatment of neovascular
AMD due to its low cost and similar efficacy, with proper
treatment schedule [14, 15].
According to the bevacizumab for Neovascular AgeRelated Macular Degeneration (ABC trial), there was a
statistically significant gain of ≥15 letters among 33% of
patients compared to 3% in the standard of care (receiving
verteporfin PDT or pegaptanib) and sham groups at the end
of one year of study. Two out of 65 patients treated with
IVT bevacizumab suffered from intraocular inflammation
including iritis, iridocyclitis, vitritis, and anterior chamber
inflammation. Systemic SAEs also occurred in 4.6% of
patients (1 atrial fibrillation and 2 myocardial infarctions) in
the treatment arm [16].
The Comparison of Age-Related Macular Degeneration
Treatments Trial (CATT) was a multicenter study that
included 1208 patients who were treated with ranibizumab
or bevacizumab either monthly or as needed with monthly
followup. The results showed that bevacizumab is equivalent
to ranibizumab with a visual acuity gain of 8.0 and 8.5 letters,
respectively, at one-year followup [17]. The two-year results
revealed equivalence (noninferiority) between the two agents
in therapeutic benefit and associated adverse effects in favor
of monthly treatment over the as-needed regimen. There was
a slightly higher number of systemic AEs among patients who
were treated with bevacizumab [18].
The interim one-year results of the ranibizumab versus bevacizumab to treat Neovascular Age-Related Macular
Degeneration (the IVAN Study), which enrolled 610 patients
with treatment-naı̈ve neovascular AMD, showed noninferiority of bevacizumab to ranibizumab in safety and efficacy,
both in the monthly and the as-needed regimens [19].
2.3.4. Aflibercept (Eylea, Regeneron, Tarrytown, NY, USA).
Aflibercept (also known as VEGF-Trap) is a human recombinant fusion protein which consists of extracellular domains
of VEGF receptor 1 and 2 (VEGFR-1 and -2) fused with Fc
portion of IgG1. It binds to VEGF-A, VEGF-B, and placental
growth factor (PlGF) [20]. It has a higher affinity for VEGF
compared to other anti-VEGFs, including bevacizumab and
ranibizumab [21].
The Clinical Evaluation of Antiangiogenesis in the Retina
Intravitreal Trial 2 (CLEAR-IT 2) is a phase II clinical trial
of VEGF Trap-Eye with monthly injection of 0.5 mg or
2 mg aflibercept for the first three months followed by PRN
administration from months 4 to 12. Combination of all
groups showed a mean gain of VA of 5.7 letters at week 12
and 5.3 letters at week 52 (𝑃 < 0.0001) [20, 22]. Ocular
AEs of aflibercept included conjunctival hemorrhage (38.2%,
5.6%), retinal hemorrhage (14.0%, 11.3%), subjective visual
loss (13.4%, 6.3%), vitreous detachment (11.5%, 7.3%), and eye
pain (9.6%, 11.4%) at the end of the study [20, 23].
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet AgeRelated Macular Degeneration (VIEW 1 and VIEW 2 studies)
are two parallel, similarly designed, phase III clinical trials
comparing efficacy and safety of aflibercept and ranibizumab
for treatment of neovascular AMD. A total of 2419 patients
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with active subfoveal or juxtafoveal CNV with leakage involving the fovea were enrolled in the two studies. In VIEW 1,
patients were recruited from 154 sites in the United States
and Canada and in VIEW 2, patients were recruited from 172
sites in Europe, Middle East, Asia, and Latin America. The
two studies showed that IVT aflibercept given every 2 months
after 3 consecutive monthly injections is equivalent in efficacy
and safety to monthly ranibizumab. Thus, aflibercept offers
a potential advantage of lessening the burden of monthly
evaluations and treatments as well as decreasing the potential
risks associated with monthly IVT injections [24].

3. New Emerging Therapies
3.1. Small Interfering RNA (siRNA). The role of messenger
RNA (mRNA) in the production of protein is very crucial.
Translation of single mRNA can lead to the production of
up to 5,000 copies of a protein molecule. Hence, one can
recognize the importance of RNA interference in inhibition
of protein assembly by blocking the amplification step in
protein synthesis.
siRNA is incorporated into the RNA-Induced Silencing
Complex (RISC) inside the cell, enhancing the helicase
activity of this complex and leading to selective and potent
cleavage and degradation of the mRNA. The siRNA can be
engineered to match a specific nucleotide sequence of a target
mRNA [25].
(1) siRNA 027 (AGN211745) is a small interfering RNA
that targets VEGFR-1 on the endothelial cells, which
in turn mediates new blood vessels formation when
stimulated by VEGF or PlGF. IVT injection of siRNA
027 in mice reduced the VEGFR-1 mRNA levels
and suppressed the development of CNV at rupture
sites of Bruch’s membrane as well as decreased retinal neovascularization in oxygen-induced ischemic
retinopathy [26, 27]. A dose escalating study of (up
to 1600 𝜇g) IVT injection of siRNA in 26 patients
showed tolerability and stabilization or improvement
of VA in cases with neovascular AMD refractory to
other types of treatment [28].
(2) siRNA PF-04523655 (REDD14) inhibits the expression of hypoxia-induced gene RTP801, which in
turn inhibits activation of the mammalian target of
rapamycin (mTOR) pathway leading to reduction of
VEGF-A production. An additional antiangiogenic
effect of mTOR inhibition is achieved by decreasing
the response of endothelial cells to VEGF through
intracellular signal suppression. In the evaluation
of the siRNA PF-04523655 versus ranibizumab for
the treatment of neovascular AMD (MONET study),
the combination of PF-04523655 with ranibizumab
achieved better improvement in BCVA (9.5 letters) than ranibizumab monotherapy group (6.8 letters), which achieved better improvement than PF04523655 monotherapy (<4 letters), with no safety
concerns among the three groups. However, these
observations were not statistically significant [29].
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3.2. Other Antagonists to the VEGF Pathway
3.2.1. Sphingosine-1-phosphate (S1P) Antibody. S1P is a bioactive lipid mediator whose biological activities are moderated
via G protein-coupled cell surface receptors that are found on
endothelial cells. It is proposed that retinal pigment epithelial
cells (RPE) are a major source of S1P in the retina and that
the S1P stored and released from RPE is responsible for
the pathological angiogenesis, vascular permeability, fibrosis,
and inflammatory responses associated with neovascular
AMD [30].
Sonepcizumab is a monoclonal antibody that selectively
binds to S1P. It was evaluated in mice with oxygen-induced
ischemic retinopathy and was found to cause decreased
inflow of macrophages into the retina, suppression of retinal
neovascularization, and reduced CNV in mice after laser disruption of Bruch’s membrane [30]. iSONEP (Lpath, Inc.), the
ocular formulation of sonepcizumab, was administered IVT
to subjects with CNV secondary to AMD. Results showed
regression (>75%) in the CNV lesion in 3 out of 4 patients
with occult lesions and resolution of RPE detachment [31].
iSONEP is currently being evaluated in additional clinical
trials (clinical trial identifier is NCT01414153) to confirm its
efficacy [32].
3.2.2. Squalamine Lactate. Squalamine lactate is an antiangiogenic compound that belongs to the aminosterol class of
drugs. It blocks off cell membrane ion transporters that are
responsible for keeping cell function in check. Squalamine
blocks the action of VEGF and integrin expression when
bound to calmodulin, thereby preventing angiogenesis. A
phase I/II clinical trial enrolled 40 patients with neovascular
AMD and showed vision stability in patients receiving weekly
25 mg/m2 and 50 mg/m2 of intravenous squalamine lactate
(Evizon, Genaera Corporation, Plymouth Meeting, PA) with
potential increase in VA in 26% of patients. However, the
intravenous formula of the drug was terminated by Genaera
and is no longer in clinical development for AMD [31]. A
randomized clinical trial evaluating the efficacy and safety of
topical squalamine lactate for the treatment of neovascular
AMD is currently recruiting patients (clinical trial identifier
is NCT01678963) [33].
3.2.3. Palomid 529. Palomid 529 prevents angiogenesis by
inhibiting the mammalian target of rapamycin (Akt/mTOR)
signal transduction pathway and causing dissociation of
rapamycin complexes, TORC1 and TORC2. Animal studies
have shown that palomid 529 reduces proliferation and
stabilizes the structure of vessels already formed [34]. A phase
I trial testing the safety and efficacy of palomid 529 in patients
with neovascular AMD who have not responded to antiVEGF treatments has been completed. However, the results
have not yet been published [35].
3.2.4. KH902. KH902 is a recombinant, soluble, VEGFR
protein in which the binding domains of VEGF receptors
1 and 2 are combined with the Fc portion of IgG. The
receptor portion of the molecule has a very high affinity
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for all VEGF-A isoforms, PlGF 1 and 2, and VEGF-B [36].
It has similar properties as aflibercept. KH902 has been
shown to reduce laser-induced choroidal neovascularization
in monkeys. In a phase I dose escalating study, 28 patients
with neovascular AMD were given a single IVT injection
of 0.05 mg, 0.15 mg, 0.5 mg, 1.0 mg, 2.0 mg, and 3.0 mg
KH902 and followed up for 12 weeks. No safety concerns
were detected and bioactivity of KH902 was suggested with
improvement in VA, reduction in central retinal thickness,
and reduction in CVN area in patients with exudative AMD
[37]. Further studies are being planned.
3.2.5. AAV2-sFLT01. Intravitreal injection of adeno-associated viral (AAV2) vector is being used to deliver an antiVEGF molecule, sFLT01. AAV2 vectors have minimal toxicity
with a potential for long-term expression [38]. Two studies
were performed on cynomolgus monkeys to evaluate the
efficacy of AAV2-sFLT01. In the first study, the study eye was
treated by 2 × 108 or 2 × 109 vector genomes (vg) and the
contralateral eye was treated by the same dose of AAV2 vector
that does not encode for a transgene (AAV2-Null). Laserinduced CNV occurred 6 weeks later in both groups. None
of the treatment eyes demonstrated a statistically significant
reduction of CNV leakage compared to the AAV2-Null
control eyes. In the second study, dosage was increased to 2 ×
1010 vg in the study eye with no treatment in the contralateral
eye. Laser induced CNV occurred at week 22. Statistically
significant reduction of CNV leakage was observed in the
treated eyes with only 7% of the treated burns showed leakage
compared to 56% of burns in the control eyes. The technology
of AAV2-sFLT01 warrants further evaluation to study its
potential benefits of long term protection and limited number
of injections [39].
3.2.6. MP0112. MP0112 is a designed ankyrin repeat protein
(DARPin) based antiangiogenic drug that specifically binds
all VEGF-A isoforms. Animal studies indicated a potential
of reducing the dosing frequency in humans by 3 to 4
folds compared to current standard therapies [40]. A phase
I/II escalating dose multicenter clinical trial investigated the
safety and efficacy of intravitreal injection of MP0112 for
neovascular AMD over a span of 16 weeks (clinical trial
identifier is NCT01086761). However, the study has been
terminated by the sponsor after completion of part A of the
study and results have not yet been published [41].
3.3. Tyrosine Kinase Inhibitors. The biological activity of
VEGF is mediated by the VEGFRs. VEGFR-1 and -2 are
receptor tyrosine kinases [42]. Therefore, inhibition of tyrosine kinase seems to be a potential therapeutic option for
treatment of neovascular AMD.
3.3.1. Vatalanib. Vatalanib is a powerful tyrosine kinase
inhibitor with activity against the platelet derived growth
factor receptor (PDGFR) and c-Kit receptor kinases. Preclinical studies have demonstrated that this drug prevents
angiogenesis [43]. A phase I/II trial to evaluate the safety
and efficacy of oral vatalanib combined with PDT has been
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completed (clinical trial identifier is NCT00138632); the
results, however, have not been published yet [44].
3.3.2. Pazopanib. Pazopanib is a new generation tyrosine
kinase inhibitor against VEGFR, PDGFR, and c-kit [45]. A
phase I clinical trial with topical pazopanib in 38 subjects has
successfully demonstrated its safety and tolerability. A phase
II trial to evaluate its pharmacodynamics, pharmacokinetics,
and safety has been completed. However, the results have not
been published yet (clinical trial identifier is NCT01072214)
[46].
3.4. Radiation. Commonly used anti-VEGF treatments for
AMD usually suppress rather than eliminate the disease
and usually involve repeated IVT injections. Radiation is
a promising and noninvasive therapeutic option that can
eliminate the ability of pathologic vascular endothelial cells
to replicate, thereby impairing their function and leading
to their cellular death. Thus, it may help to decrease the
frequency of anti-VEGF IVT injections [47].
3.4.1. IRay. The IRay system is an emerging noninvasive
therapeutic option for neovascular AMD. The system delivers
3 overlapping beams through the inferior pars plana to
the macula. The spot size of each beam is 3.5 mm at the
sclera which gives a 4 mm spot size at the macula. With
the overlapping between the 3 beams the effective spot size
achieved at the macula is approximately 6 mm. The patient’s
eligibility for treatment is determined based on the proximity
of the optic nerve to the macula [48].
Radiation retinopathy does not usually occur until a dose
of 45 Gy is delivered to the retina typically after 2.5 years.
Since IRay uses doses of either 16 Gy or 24 Gy, this may
decrease the likelihood of radiation retinopathy and makes it
a plausible mode of treatment [49]. The IRay Plus Anti-VEGF
Treatment for Patients with Neovascular AMD (INTREPID)
study is ongoing and aims to evaluate the effectiveness
and safety of a one-time radiation therapy with juxtaposed
administration of as-needed anti-VEGF injections for treating neovascular AMD [50].
3.4.2. Epiretinal Macular Brachytherapy (EMB). EMB is a
new treatment option for neovascular AMD. By allowing the
Strontium-90 (Sr90) source to be placed close to the highly
diseased area with approximately 5 mm retinal penetration,
it enables targeted delivery of radiation to the neovascular
tissue [51] and prevent nonocular exposure. Using a 24 Gy
source, the required dose can be delivered within 3 to 4
minutes [52].
A small scale study yielded positive results for the use
of EMB in adjunct with bevacizumab with a mean gain
of 8.9 letters in VA at 12 months [53]. However, the Epimacular Brachytherapy for Neovascular Age-related Macular
Degeneration (CABERNET) study, a multicenter trial, did
not endorse the use of EMB as a monotherapy [47, 54]. The
mean VA change at Month 12 compared to baseline for EMB
was −0.5 letters with relatively higher incidence of cataract
formation and disease progression.
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The Macular Epiretinal Brachytherapy in Treated Agerelated Macular Degeneration (MERITAGE) study showed
relatively favorable results for EMB. Visual improvement was
observed in 47.2% of the participants, with decreased required
number of anti-VEGF injections to 3 injections only over
the 12 month period in more than 50% of participants. Subconjunctival hemorrhages were commonly reported whereas
no cases of radiation retinopathy were reported during the
course of the study, albeit it was short [55].
Overall, radiation may have potential therapeutic effects;
thus far, no study has confirmed its role in the management
of neovascular AMD.
3.5. Others
3.5.1. Platelet Derived Growth Factor Antagonists: E10030. In
order for newly sprouting vessels to mature and stabilize,
endothelial cells need to be coated by pericytes. A key
mediator of this process is the platelet-derived growth factor
beta (PDGF-𝛽) [56]. Inhibitors of PDGF-𝛽 such as the
pegylated aptamer E10030 (Ophthotech) have been demonstrated to prevent this process, thereby making nascent
blood vessels susceptible to VEGF inhibition. Safety and
pharmacokinetic profile of E10030 have also been evaluated
as a monotherapy or in conjunction with ranibizumab in
treating neovascular AMD patients [57]. Furthermore, a
phase II study to assess the safety and efficacy of E10030 in
combination with ranibizumab has been completed (clinical
trial identifier is NCT01089517) [58]. Preliminary results
showed that combination of E10030 and ranibizumab was
superior to ranibizumab monotherapy [59].

4. Expert Opinion
The last decade has been a remarkable period for the
management of neovascular AMD. Clinician scientists have
come far from witnessing patients lose their sights to reviving their vision with new therapies. Since the arrival of
photodynamic therapy which, for the first time, stabilized
vision, there has been significant advances in the treatment
of neovascular AMD with the use of VEGF inhibitors [60,
61]. In the pioneering ANCHOR and MARINA studies, the
fluorescein angiography (FA) showed reduction in vascular
permeability, leakage, and edema, but the actual structural
changes underlying exudative disease remained unaffected
by the treatment. The CATT and VIEW studies were able
to confirm the effectiveness of VEGF antagonists including
bevacizumab, ranibizumab, and aflibercept. A new treatment
modality, the antiplatelet derived growth factor (anti-PDGF)
agent, has shown the ability to induce neovascular membrane
regression and, when used in combination with ranibizumab,
produce additional vision gain than anti-VEGF monotherapy.
There is a consensus on several susceptibility genes for
AMD, most notably complement factor H, and LOC387715/
ARMS2 [62], which have been shown to affect the patient’s
response to treatment [63]. Other pharmacological agents
and approaches are being evaluated as potential therapies for
neovascular AMD as well. These drugs act through different mechanisms, such as modulating the anti-inflammatory
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response, which may complement current therapies very
appropriately. The future of neovascular AMD will very likely
depend on our understanding and application of possible
combination therapies of different agents and approaches.
Further research is warranted in order to achieve this goal
and, fortunately, is occurring throughout the world [64].
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